| RS2135849163 |
MYRF
|
Health Risk |
Likely pathogenic |
— |
| RS2135850957 |
HNF1A
|
Health Risk |
Pathogenic |
Monogenic diabetes, Maturity-onset diabetes of the young type 3 |
| RS2135851223 |
HNF1A
|
Health Risk |
Pathogenic |
— |
| RS2135851518 |
HNF1A
|
Health Risk |
Pathogenic |
Monogenic diabetes, Monogenic diabetes |
| RS2135851715 |
HNF1A
|
Health Risk |
Likely pathogenic |
HNF1A-related disorder, HNF1A-related disorder |
| RS2135854397 |
HNF1A
|
Health Risk |
Likely pathogenic |
Monogenic diabetes, Monogenic diabetes |
| RS2135854451 |
HNF1A
|
Health Risk |
Pathogenic |
Maturity-onset diabetes of the young type 3, Monogenic diabetes |
| RS2135854461 |
HNF1A
|
Health Risk |
Likely pathogenic |
Keratoderma-ichthyosis-deafness syndrome, autosomal recessive |
| RS2135854520 |
HNF1A
|
Health Risk |
Likely pathogenic |
Monogenic diabetes, Monogenic diabetes |
| RS2135854597 |
HNF1A
|
Health Risk |
Pathogenic |
Monogenic diabetes, Monogenic diabetes |
| RS2135854670 |
HNF1A
|
Health Risk |
Likely pathogenic |
Monogenic diabetes, Monogenic diabetes |
| RS2135856266 |
PTPN11
|
Health Risk |
Pathogenic |
RASopathy, RASopathy |
| RS2135856711 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2135856808 |
MYRF
|
Health Risk |
Likely pathogenic |
MYRF-related disorder, MYRF-related disorder |
| RS2135857103 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135861085 |
MYRF
|
Health Risk |
Likely pathogenic |
— |
| RS2135861273 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135861602 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Familial cancer of breast, Ataxia-telangiectasia syndrome |
| RS2135861836 |
PTPN11
|
Health Risk |
Likely pathogenic |
— |
| RS2135861869 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135862010 |
PTPN11
|
Health Risk |
Likely pathogenic |
Noonan syndrome, Noonan syndrome |
| RS2135862367 |
PTPN11
|
Health Risk |
Pathogenic |
RASopathy, RASopathy |
| RS2135862582 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135866639 |
SUFU
|
Health Risk |
Pathogenic |
Oculomotor apraxia, Oculomotor apraxia |
| RS2135866938 |
PTPN11
|
Health Risk |
Likely pathogenic |
RASopathy, RASopathy |
| RS2135867122 |
SUFU
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder |
| RS2135867131 |
SUFU
|
Health Risk |
Pathogenic |
Gorlin syndrome, Medulloblastoma |
| RS2135867295 |
SUFU
|
Health Risk |
Pathogenic |
Gorlin syndrome, Medulloblastoma |
| RS2135867567 |
PTPN11
|
Health Risk |
Likely pathogenic |
RASopathy, RASopathy |
| RS2135870609 |
SUFU
|
Health Risk |
Pathogenic |
Gorlin syndrome, Medulloblastoma |
| RS2135870923 |
SUFU
|
Health Risk |
Likely pathogenic |
Medulloblastoma, Gorlin syndrome |
| RS2135870931 |
SUFU
|
Health Risk |
Likely pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2135879026 |
PEX5
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 2B, Peroxisome biogenesis disorder 2B |
| RS2135879573 |
ATP6V0A2
|
Health Risk |
Likely pathogenic |
ALG9 congenital disorder of glycosylation, ALG9 congenital disorder of glycosylation |
| RS2135879752 |
ATP6V0A2
|
Health Risk |
Pathogenic |
— |
| RS2135880243 |
PEX5
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 2B, Rhizomelic chondrodysplasia punctata type 5 |
| RS2135881899 |
SUFU
|
Health Risk |
Pathogenic |
Gorlin syndrome, Medulloblastoma |
| RS2135882176 |
SUFU
|
Health Risk |
Conflicting classifications of pathogenicity |
Gorlin syndrome, Medulloblastoma |
| RS2135882212 |
SUFU
|
Health Risk |
Pathogenic |
Medulloblastoma, Gorlin syndrome |
| RS2135882232 |
SUFU
|
Health Risk |
Pathogenic |
Medulloblastoma, Gorlin syndrome |
| RS2135882474 |
UNG
|
Health Risk |
Pathogenic |
Hyper-IgM syndrome type 5, Hyper-IgM syndrome type 5 |
| RS2135886253 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2135887401 |
ATP6V0A2
|
Health Risk |
Pathogenic |
ALG9 congenital disorder of glycosylation, ALG9 congenital disorder of glycosylation |
| RS2135887733 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Ataxia-telangiectasia syndrome, Hereditary cancer-predisposing syndrome |
| RS2135888102 |
ATM
|
Health Risk |
Pathogenic |
Familial cancer of breast, Familial cancer of breast |
| RS2135888594 |
SUFU
|
Health Risk |
Pathogenic |
Medulloblastoma, Gorlin syndrome |
| RS2135889203 |
SUFU
|
Health Risk |
Pathogenic |
Gorlin syndrome, Medulloblastoma |
| RS2135889249 |
SUFU
|
Health Risk |
Pathogenic |
Gorlin syndrome, Hereditary cancer-predisposing syndrome |
| RS2135889257 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135890847 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Familial cancer of breast |
| RS2135891669 |
ATM
|
Health Risk |
Pathogenic |
Malignant tumor of urinary bladder, Familial cancer of breast |
| RS2135892447 |
SOX5
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2135892544 |
KIF11
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2135893101 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135893222 |
ATM
|
Health Risk |
Pathogenic/Likely pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135893427 |
ATM
|
Health Risk |
Likely pathogenic |
Hereditary cancer-predisposing syndrome, Ataxia-telangiectasia syndrome |
| RS2135894892 |
SOX5
|
Health Risk |
Pathogenic |
Lamb-Shaffer syndrome, Lamb-Shaffer syndrome |
| RS2135897895 |
MYRF
|
Health Risk |
Likely pathogenic |
Cardiac-urogenital syndrome, Cardiac-urogenital syndrome |
| RS2135900558 |
KIF11
|
Health Risk |
Pathogenic |
Microcephaly with or without chorioretinopathy, lymphedema |
| RS2135900803 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135901005 |
PTPN11
|
Health Risk |
Conflicting classifications of pathogenicity |
LEOPARD syndrome 1, Noonan syndrome 1 |
| RS2135901128 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135901148 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135901156 |
KIF11
|
Health Risk |
Likely pathogenic |
Microcephaly with or without chorioretinopathy, lymphedema |
| RS2135901920 |
PTPN11
|
Health Risk |
Likely pathogenic |
Metachondromatosis, Metachondromatosis |
| RS2135902166 |
PTPN11
|
Health Risk |
Likely pathogenic |
Metachondromatosis, Metachondromatosis |
| RS2135902177 |
PTPN11
|
Health Risk |
Pathogenic |
RASopathy, RASopathy |
| RS2135902386 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135902414 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135902435 |
KIF11
|
Health Risk |
Likely pathogenic |
Microcephaly with or without chorioretinopathy, lymphedema |
| RS2135902897 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135902899 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135902915 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135903791 |
PC
|
Health Risk |
Pathogenic/Likely pathogenic |
Pyruvate carboxylase deficiency, Pyruvate carboxylase deficiency |
| RS2135903939 |
PEX5
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 2B, Peroxisome biogenesis disorder 2B |
| RS2135904246 |
STT3A
|
Health Risk |
Conflicting classifications of pathogenicity |
Congenital disorder of glycosylation, type Iw |
| RS2135904801 |
PC
|
Health Risk |
Pathogenic |
Pyruvate carboxylase deficiency, Pyruvate carboxylase deficiency |
| RS2135904871 |
KIF11
|
Health Risk |
Likely pathogenic |
Microcephaly with or without chorioretinopathy, lymphedema |
| RS2135904903 |
KIF11
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder |
| RS2135904919 |
KIF11
|
Health Risk |
Likely pathogenic |
Microcephaly with or without chorioretinopathy, lymphedema |
| RS2135905068 |
KIF11
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurodevelopmental delay, Microcephaly with or without chorioretinopathy |
| RS2135907187 |
KIF11
|
Health Risk |
Pathogenic |
— |
| RS2135909614 |
ATP6V0A2
|
Health Risk |
Likely pathogenic |
— |
| RS2135909683 |
ATP6V0A2
|
Health Risk |
Likely pathogenic |
— |
| RS2135911351 |
ATM
|
Health Risk |
Likely pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135911500 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Familial cancer of breast |
| RS2135912260 |
PTPN11
|
Health Risk |
Pathogenic |
— |
| RS2135912272 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135912697 |
EXPH5
|
Health Risk |
Pathogenic |
Epidermolysis bullosa simplex 4, localized or generalized intermediate |
| RS2135912726 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135912935 |
CEP164
|
Health Risk |
Likely pathogenic |
Nephronophthisis 15, Nephronophthisis 15 |
| RS2135913350 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Ataxia-telangiectasia syndrome |
| RS2135914599 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135914733 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Familial cancer of breast |
| RS2135915213 |
PFKM
|
Health Risk |
Conflicting classifications of pathogenicity |
Glycogen storage disease, type VII |
| RS2135915222 |
PTPN11
|
Health Risk |
Likely pathogenic |
RASopathy, RASopathy |
| RS2135915377 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2135916018 |
PTPN11
|
Health Risk |
Likely pathogenic |
RASopathy, RASopathy |
| RS2135916021 |
ATM
|
Health Risk |
Likely pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135916225 |
KIF11
|
Health Risk |
Pathogenic |
— |